Novimmune names business head
This article was originally published in Scrip
Executive Summary
Geneva, Switzerland-based Novimmune has appointed Adrian Mills chief business officer and member of its executive committee, with immediate effect. Mr Mills will lead Novimmune's commercial development activities as well as business development. He joins Novimmune from GlaxoSmithKline where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently Mr Mills was European commercial director for rare and critical diseases. He succeeds David Slack who is leaving Novimmune to focus on opportunities outside the company.